VISN 22 Drug Monograph Template
This trial determined that the natalizumab and placebo groups had similar rates of response (56 percent and 49 percent, respectively; P=0.05) and remission (37 percent and 30 percent, respectively; P=0.12) at 10 weeks. Additionally, natalizumab induced significantly greater clinical response in patients previously treated with infliximab (p=0.004). ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.